Emergent Biosolutions Inc. Stock
A loss of -2.040% shows a downward development for Emergent Biosolutions Inc..
Based on 2 Buy predictions and 3 Sell predictions the sentiment towards Emergent Biosolutions Inc. is rather balanced.
With a target price of 4 € there is a slightly negative potential of -11.31% for Emergent Biosolutions Inc. compared to the current price of 4.51 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Emergent Biosolutions Inc. | -2.040% | -12.338% | 126.463% | -41.905% | 106.643% | -90.404% | -88.442% |
Ironwood Pharmaceuticals | 0.840% | -0.826% | -20.000% | -37.500% | -41.176% | -40.594% | - |
Novocure Ltd | 0.090% | 13.230% | 93.040% | -70.693% | 53.485% | -85.261% | - |
Iovance Biotherapeutics Inc. | -1.490% | -2.727% | -10.108% | 29.434% | 22.439% | -35.493% | - |
Comments
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) was upgraded by analysts at Benchmark Co. from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Show more
Ratings data for EBS provided by MarketBeat